OptiBiotix Health PLC Director's dealing (6755D)

TIDMOPTI

RNS Number : 6755D

OptiBiotix Health PLC

01 February 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Director's dealing

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes was notified today that Neil Davidson, Non-Executive Chairman of the Company, today acquired 165,000 ordinary shares in the Company via his SIPP, representing 0.21% of the Company's issued share capital, at a price of 60 pence per share.

Previously to this notification Mr Davidson did not hold any shares in the Company.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Mark Collingbourne, Chief Financial Officer.

For further information, please contact:

 
 OptiBiotix Health plc                                                  www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                               Contact via 
                                                                            Walbrook below 
 
 Cairn Financial Advisers LLP                                                Tel: [phone] 
                                                                                      0880 
 Liam Murray / Jo Turner 
 
 finnCap Broker                                                              Tel: [phone] 
                                                                                      0500 
 Adrian Hargrave / Scott Mathieson 
  / Kate Bannatyne (Corporate Finance) 
 Tony Quirke (Corporate Broking) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Anna Dunphy                                                                Mob: [phone] 
                                                                                       001 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

 
 Notification of a Transaction pursuant to Article 
  19(1) of Regulation (EU) No. 596/2014 
-------------------------------------------------------------------------- 
 1      Details of the person discharging managerial 
         responsibilities/person closely associated 
-----  ------------------------------------------------------------------- 
 a.     Name                          Neil Davidson 
-----  ----------------------------  ------------------------------------- 
 2      Reason for 
         notification 
-----  ----------------------------  ------------------------------------- 
 a.     Position/Status               Non-Executive Chairman 
-----  ----------------------------  ------------------------------------- 
 b.     Initial notification/         Initial Notification 
         Amendment 
-----  ----------------------------  ------------------------------------- 
 3      Details of the issuer, emission allowance 
         market participant, auction platform, auctioneer 
         or auction monitor 
-----  ------------------------------------------------------------------- 
 a.     Name                          OptiBiotix Health plc 
-----  ----------------------------  ------------------------------------- 
 b.     LEI                           213800UKYQFT941QHS14 
-----  ----------------------------  ------------------------------------- 
 4      Details of the transaction(s): section to 
         be repeated for (i) each type of instrument; 
         (ii) each type of transaction; (iii) each 
         date; and (iv) each place where transactions 
         have been conducted 
-----  ------------------------------------------------------------------- 
 a.     Description 
         of the financial              Ordinary shares 
         instrument, 
         type of instrument 
                                       ISIN: GB00BP0RTP38 
         Identification 
         Code 
-----  ----------------------------  ------------------------------------- 
 b.     Nature of the                  Purchase of ordinary shares 
         transaction 
-----  ----------------------------  ------------------------------------- 
 
 c.     Price(s) and                   Price(s)            Volume(s) 
         volume(s)                      per share 
-----  ----------------------------   ------------------  ------------ 
 
      60 pence                                               165,000 
   -----------------------------------------------------  ------------ 
 
 d.     Aggregated 
         information 
                                        165,000 
         - Aggregated 
         Volume                         60 pence 
 
         - Price 
-----  ----------------------------  ------------------------------------- 
 e.     Date of the                   1 February 2018 
         transaction 
-----  ----------------------------  ------------------------------------- 
 f.     Place of the                  AIM 
         transaction 
-----  ----------------------------  ------------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHZFLFBVLFLBBB

(END) Dow Jones Newswires

February 01, 2018 09:22 ET (14:22 GMT)